Related Experiment Video
Updated: Jul 15, 2026
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Rodent models of streptozotocin-induced diabetic nephropathy
1Department of Nephrology, Monash University, Monash Medical Centre, Clayton, Victoria, Australia. greg.tesch@med.monash.edu.au
Abstract:
Streptozotocin-induced pancreatic injury is commonly used for creating rodent models of type 1 diabetes which develop renal injury with similarities to human diabetic nephropathy. This model can be established in genetically modified rodents for investigating the role of molecular mechanisms and genetic susceptibility in the development of diabetic nephropathy. In this report, the authors describe and compare the current protocols being used to establish models of diabetic nephropathy in rat and mouse strains using streptozotocin. The authors also list some of the histological criteria and biochemical measurements which are being used to validate these models. In addition, our review explains some of the key aspects involved in these models, including the impact of streptozotocin-dosage, uninephrectomy, hypertension and genetically modified strains, which can each affect the development of disease and the interpretation of findings.
Insights
Streptozotocin creates rodent models of type 1 diabetes and diabetic nephropathy. This review compares protocols and factors influencing these models for research.
Area of Science:
- Endocrinology and Metabolism
- Nephrology
- Animal Models of Disease
Background:
- Streptozotocin-induced pancreatic injury in rodents is a key model for type 1 diabetes.
- This model exhibits renal injury similar to human diabetic nephropathy.
- Genetically modified rodents can be used to study molecular mechanisms of diabetic nephropathy.
Purpose of the Study:
- To describe and compare current protocols for establishing diabetic nephropathy models in rats and mice using streptozotocin.
- To review histological criteria and biochemical measurements for validating these models.
- To discuss key factors influencing disease development and findings in these models.
Main Methods:
- Review and comparison of existing streptozotocin-induced diabetic nephropathy protocols in rat and mouse strains.
- Identification of histological and biochemical validation methods.
- Analysis of factors affecting model outcomes, including streptozotocin dosage, uninephrectomy, hypertension, and genetic modifications.
Main Results:
- Detailed comparison of protocols for establishing streptozotocin-induced diabetic nephropathy models.
- Listing of established histological and biochemical validation criteria.
- Identification of critical factors (streptozotocin dosage, uninephrectomy, hypertension, genetic background) influencing model outcomes.
Conclusions:
- Streptozotocin-induced rodent models are valuable for studying diabetic nephropathy.
- Standardized protocols and validation methods are crucial for reliable research.
- Understanding influencing factors is essential for accurate interpretation of experimental findings.
